July 13, 2017
Evelo Biosciences raises a $50,000,000 series B round from Flagship Pioneering.
Evelo Biosciences raises a $50,000,000 series B round from Celgene, Flagship Pioneering and Mayo Clinic.
July 8, 2021
PlateletBio Names Derek Adams, Ph.D., as Chief Operating Officer - read this article along with other careers information, tips and advice on BioSpace
June 1, 2021
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the appointment of Mark Plinio as Chief Commercial Officer, effective June 14, 2021.
May 13, 2021
On-track to initiate clinical development of EDP2939 in 2022
April 20, 2021
-Evelo presents late-breaking abstract at the International Society of Atopic Dermatitis Annual Meeting- -Meaningful improvements over placebo on clinical scores, including new data released on key IGA endpoints- -Initiation of Phase 2 trial of EDP1815 in atopic dermatitis expected in 3Q 2021-
April 16, 2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Company Operating Status
Number of Employees (Ranges)
100 – 249
620 Memorial Drive, 5th Floor Cambridge, MA, 02139 USA
Place of Incorporation
Total Funding Amount (USD)
Latest Funding Round Date
July 13, 2017
Latest Funding Type